

Accepted Manuscript

Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma

Pilar de la Puente, Micah J. Luderer, Cinzia Federico, Abbey Jin, Rebecca C. Gilson, Christopher Egbulefu, Kinan Alhallak, Shruti Shah, Barbara Muz, Jennifer Sun, Justin King, Daniel Kohnen, Noha Nabil Salama, Samuel Achilefu, Ravi Vij, Abdel Kareem Azab



PII: S0168-3659(17)31052-0
DOI: doi:[10.1016/j.jconrel.2017.11.045](https://doi.org/10.1016/j.jconrel.2017.11.045)
Reference: COREL 9075
To appear in: *Journal of Controlled Release*
Received date: 3 August 2017
Revised date: 29 October 2017
Accepted date: 27 November 2017

Please cite this article as: Pilar de la Puente, Micah J. Luderer, Cinzia Federico, Abbey Jin, Rebecca C. Gilson, Christopher Egbulefu, Kinan Alhallak, Shruti Shah, Barbara Muz, Jennifer Sun, Justin King, Daniel Kohnen, Noha Nabil Salama, Samuel Achilefu, Ravi Vij, Abdel Kareem Azab , Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Corel(2017), doi:[10.1016/j.jconrel.2017.11.045](https://doi.org/10.1016/j.jconrel.2017.11.045)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma

Pilar de la Puente¹, Micah J. Luderer¹, Cinzia Federico¹, Abbey Jin^{1,2}, Rebecca C. Gilson³, Christopher Egbulefu³, ,**Kinan Alhallak¹**, **Shruti Shah¹**, Barbara Muz¹, **Jennifer Sun¹**, Justin King⁴, Daniel Kohnen⁴, Noha Nabil Salama^{2,5}, Samuel Achilefu³, Ravi Vij⁴,
and Abdel Kareem Azab^{1,*}

¹Department of Radiation Oncology, Washington University in Saint Louis School of Medicine, MO, USA ² Department of Pharmaceutical and Administrative Sciences, St. Louis College of Pharmacy, MO, USA ³ Mallinckrodt Institute of Radiology, Washington University School of Medicine, MO, USA ⁴ Section of Stem Cell Transplant and Leukemia, Division of Medical Oncology, ⁵ Department of Pharmaceutics and Industrial Pharmacy, Cairo University Faculty of Pharmacy, Cairo, Egypt.

* Corresponding Author:

Abdel Kareem Azab, Ph.D., B. Pharm.

Department of Radiation Oncology

Cancer Biology Division

Washington University in Saint Louis School of Medicine

4511 Forest Park Ave., Room 3103

St. Louis, MO 63108

Office (314) 362-9254; Fax (314) 362-9790

Email: kareem.azab@wustl.edu

Download English Version:

<https://daneshyari.com/en/article/7860480>

Download Persian Version:

<https://daneshyari.com/article/7860480>

[Daneshyari.com](https://daneshyari.com)